Amsacrine in refractory acute leukemia.

Abstract

Thirty-two patients with heavily pretreated, relapsed acute leukemia were treated with amsacrine (120 mg/m2/day X 5). The 32 patients received a total of 41 courses of therapy, and 31 patients were evaluable for response. There were no complete remissions and only one partial remission (3 months) in an adult patient with acute lymphoblastic leukemia. Toxic effects included myelosuppression (100% of the patients), hyperbilirubinemia (41%), nausea and vomiting (41%), stomatitis (9%), and cardiac dysrhythmia (3%). We conclude that amsacrine as a single agent is not a useful treatment for relapsed, heavily pretreated adult and pediatric acute leukemia.

• Authors: J D Griffin, M E Maguire, R J Mayer
• Journal: Cancer treatment reports (Cancer Treat Rep) 1985 Jul-Aug Vol. 69 Issue 7-8 Pg. 787-9 ISSN: 0361-5960 [Print] United States
• PMID: 3860296 (Publication Type: Journal Article)

Chemical References

• Aminoacridines
• Antineoplastic Agents
• Amsacrine

Topics

• Acute Disease
• Adolescent
• Adult
• Aged
• Aminoacridines (adverse effects, therapeutic use)
• Amsacrine
• Antineoplastic Agents (adverse effects, therapeutic use)
• Child
• Child, Preschool
• Drug Evaluation
• Drug Resistance
• Humans
• Hypotension (chemically induced)
• Leukemia (drug therapy)
• Leukemia, Lymphoid (drug therapy)
• Leukemia, Myeloid, Acute (drug therapy)
• Middle Aged
• Recurrence
• Tachycardia (chemically induced)